|
ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
|
5R00CA158065-05
|
$249,000
|
$249,000
|
RINK, LORI
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer
|
7R01CA186338-02
|
$347,191
|
$347,191
|
LI, MIN
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
Yap and beta-catenin interactions in liver: Implications in Pathophysiology
|
1R01CA204586-01
|
$425,315
|
$425,315
|
MONGA, SATDARSHAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S1
|
$121,550
|
$13,371
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S2
|
$60,000
|
$6,600
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S3
|
$125,625
|
$13,819
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S4
|
$200,000
|
$22,000
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S5
|
$484,876
|
$53,336
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S6
|
$502,500
|
$55,275
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
4P30CA016359-37
|
$2,600,006
|
$286,001
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Cancer Center NCTN
|
5U10CA180826-03
|
$551,500
|
$110,300
|
HOCHSTER, HOWARD
|
YALE UNIVERSITY
|
|
Xenobiotic receptors
|
ZIA BC 005562
|
$719,839
|
$539,880
|
Gonzalez, Frank
|
CCR (NCI)
|
|
Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers
|
ZIA BC 005708
|
$719,839
|
$431,904
|
Gonzalez, Frank
|
CCR (NCI)
|
|
Women's Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-04S1
|
$170,764
|
$30,738
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Women's Health Initiative Cancer Survivor Cohort
|
4UM1CA173642-04
|
$2,396,733
|
$431,412
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Wired for Colorectal Cancer Screening: An mHealth Intervention
|
1R03CA198580-01A1
|
$97,869
|
$97,869
|
DAVIS, STACY
|
RBHS-SCHOOL OF PUBLIC HEALTH
|
|
Winship Cancer Institute, National Clinical Trials Network Lead Academic Particip
|
5U10CA180864-03
|
$542,807
|
$81,421
|
RAMALINGAM, SURESH
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-08S1
|
$59,999
|
$4,800
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
4P30CA138292-08
|
$2,038,828
|
$163,106
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Whole exome sequencing of oropharyngeal carcinoma (OPX-WES)
|
5R03CA183010-02
|
$56,500
|
$56,500
|
ANANTHARAMAN, DEVASENA
|
INTERNATIONAL AGENCY FOR RES ON CANCER
|
|
Washington University/ Siteman Cancer Center Lead Academic Site
|
3U10CA180833-02S1
|
$100,000
|
$10,000
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Washington University/ Siteman Cancer Center Lead Academic Site
|
5U10CA180833-03
|
$1,649,280
|
$164,928
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Washington University SPORE in Pancreatic Cancer
|
1P50CA196510-01A1
|
$2,186,724
|
$2,186,724
|
HAWKINS, WILLIAM
|
WASHINGTON UNIVERSITY
|
|
Vitamin D and colorectal cancer risk: an integrated molecular and genetic epidemiologic study
|
1K99CA207848-01
|
$102,298
|
$102,298
|
WARREN ANDERSEN, SHANEDA
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
VIRUS DISCOVERY AND CHARACTERIZATION IN LARGE-SCALE CANCER SEQUENCING DATA
|
5R01CA178383-03
|
$255,216
|
$84,221
|
DING, LI
|
WASHINGTON UNIVERSITY
|
|
Video Informed Consent Tools to Improve Care for Patients With Advanced Pancreatic Cancer
|
1K07CA204201-01
|
$176,652
|
$176,652
|
ENZINGER, ANDREA
|
DANA-FARBER CANCER INST
|
|
VDAC Regulation of Warburg Metabolism in Hepatocarcinoma
|
1R01CA184456-01A1
|
$341,981
|
$341,981
|
MALDONADO, EDUARDO
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Vascular Biology Section
|
ZIA BC 011390
|
$1,126,266
|
$281,567
|
Lin, Pengnian Charles
|
CCR (NCI)
|
|
Variations in Needs after Colorectal Cancer Diagnosis
|
5R01CA181392-03
|
$607,762
|
$607,762
|
BOEHMER, ULRIKE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Vanderbilt Proteome Characterization Center
|
3U24CA159988-07S1
|
$225,325
|
$225,325
|
LIEBLER, DANIEL
|
VANDERBILT UNIVERSITY
|
|
Vanderbilt Network Lead Academic Participating Site for the NCTN
|
5U10CA180847-03
|
$9,808
|
$1,962
|
BERLIN, JORDAN
|
VANDERBILT UNIVERSITY
|
|
Vanderbilt Network Lead Academic Participating Site for the NCTN
|
6U10CA180847-04
|
$410,211
|
$82,042
|
BERLIN, JORDAN
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Validation of pancreatic cancer biomarkers in large prospective cohorts
|
5R01CA196286-02
|
$505,275
|
$505,275
|
LOKSHIN, ANNA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Validation of Methylated Vimentin as a Diagnostic Test for Barrett's Esophagus
|
1UH2CA205105-01
|
$346,395
|
$346,395
|
WILLIS, JOSEPH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms
|
1U01CA200466-01
|
$902,819
|
$902,819
|
BRAND, RANDALL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms
|
3U01CA200466-01S1
|
$171,812
|
$171,812
|
BRAND, RANDALL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Validation and Fine-Scale Mapping of Pancreatic Cancer Susceptibility Loci (Study)
|
2R01CA154823-05
|
$735,208
|
$735,208
|
KLEIN, ALISON
|
JOHNS HOPKINS UNIVERSITY
|
|
Validation and Extension of the PREMM Model for Inherited Colorectal Cancer
|
4R01CA132829-08
|
$449,215
|
$449,215
|
SYNGAL, SAPNA
|
DANA-FARBER CANCER INST
|
|
Validating Technology To Optimize Antibody Affinity For Targeting Therapeutics
|
5R33CA177333-03
|
$76,654
|
$25,296
|
FEDERSPIEL, MARK
|
MAYO CLINIC ROCHESTER
|
|
Vaccine and radiation for the therapy of human cancers
|
ZIA BC 010975
|
$393,241
|
$39,324
|
Hodge, James
|
CCR (NCI)
|
|
Vaccine and Drug Combination Therapy for Human Cancers
|
ZIA BC 010661
|
$393,241
|
$78,648
|
Hodge, James
|
CCR (NCI)
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-42S1
|
$125,000
|
$7,500
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
4P30CA014520-42
|
$4,288,496
|
$257,310
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
|
5U10CA180870-03
|
$645,976
|
$64,598
|
GERBER, DAVID
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
|
3U10CA180870-02S1
|
$50,000
|
$5,000
|
SCHILLER, JOAN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
|
5U10CA180858-03
|
$1,192,600
|
$119,260
|
ENG, CATHY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Using vitamin D glucuronide pro-drugs to prevent/treat colon cancer
|
2R15CA173628-02
|
$450,000
|
$450,000
|
GOFF, JESSE
|
IOWA STATE UNIVERSITY
|
|
Using the Collaborative Cross for Model Studies of Intestinal Cancer
|
1R21CA202496-01A1
|
$203,580
|
$203,580
|
SIRACUSA, LINDA
|
THOMAS JEFFERSON UNIVERSITY
|
|
Using markers to improve pancreatic cancer screening and surveillance
|
1U01CA210170-01
|
$983,899
|
$983,899
|
GOGGINS, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
|
Using markers to improve pancreatic cancer screening and surveillance
|
3U01CA210170-01S1
|
$248,872
|
$248,872
|
GOGGINS, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
Total relevant funding to Digestive Diseases for this search: $502,916,313
|